Kuhnl, Andrea;
Roddie, Claire;
Kirkwood, Amy A;
Tholouli, Eleni;
Menne, Tobias;
Patel, Amit;
Besley, Caroline;
... McMillan, Andrew; + view all
(2022)
A national service for delivering CD19 CAR-Tin large B-cell lymphoma – The UK real-world experience.
British Journal of Haematology
, 198
(3)
pp. 492-502.
10.1111/bjh.18209.
Preview |
Text
Kirkwood_Kuhnl BjH Dec 2021_revision 21.3.22 clean.pdf Download (789kB) | Preview |
Abstract
CD19 CAR-T have emerged as a new standard treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). CAR-T real-world (RW) outcomes published to date suggest significant variability across countries. We provide results of a large national cohort of patients intended to be treated with CAR-T in the UK. Consecutive patients with r/r LBCL approved for CAR-T by the National CAR-T Clinical Panel between December 2018 and November 2020 across all UK CAR-T centres were included. 404/432 patients were approved [292 axicabtagene ciloleucel (axi-cel), 112 tisagenlecleucel (tisa-cel)], 300 (74%) received the cells. 110/300 (38.3%) patients achieved complete remission (CR) at 6 months (m). The overall response rate was 77% (52% CR) for axi-cel, 57% (44% CR) for tisa-cel. The 12-month progression-free survival was 41.8% (axi-cel) and 27.4% (tisa-cel). Median overall survival for the intention-to-treat population was 10.5 m, 16.2 m for infused patients. The incidence of grade ≥3 cytokine release syndrome and neurotoxicity were 7.6%/19.6% for axi-cel and 7.9%/3.9% for tisa-cel. This prospective RW population of CAR-T eligible patients offers important insights into the clinical benefit of CD19 CAR-T in LBCL in daily practice. Our results confirm long-term efficacy in patients receiving treatment similar to the pivotal trials, but highlight the significance of early CAR-T failure.
Archive Staff Only
 |
View Item |
